drugset / Trial / NCT01139047

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin

NCT01139047

Phase 4 Completed 77 enrolled Galderma R&D
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.

Timeline

Start
2010-06
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelaic acid Small molecule 15 % Topical
Comparator Metronidazole Small molecule 1 % Topical

Indications